Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma

Table 1 Baseline characteristics of the cohort n (%)

Characteristic	Entire cohort (n = 69)
Patient age in years, median (range)	21 (14-61)
Recipient gender, male	41 (59%)
Cell subtype
B-cell	50 (72)
T-cell	19 (28)
Philadelphia chromosome (B-cell)	16/50 (32)
Disease subtype
Lymphoblastic leukemia	52 (75)
Lymphoblastic lymphoma	17 (25)
Cytogenetic status
Standard	30 (43)
High risk	35 (51)
Missing	4 (6)
ECOG, median (range)	0 (0-2)
HCT-CI, median (range)	0 (0-5)
Gender mismatch	28 (41)
Female donor/male recipient	11 (16)
Donor type
MSD	58 (84)
MORD	2 (3)
MUD	3 (4)
Haploidentical	6 (9)
Status at HCT
CR1	42 (61)
≥ CR2	27 (39)
ABO matching
Match	50 (73)
Major/bidirectional	10 (14)
Minor	9 (13)
TBI containing regimen	60 (87)
Conditioning intensity
MAC	62 (90)
RIC/NMA	7 (10)

ECOG: Eastern Cooperative Oncology Group; HCT-CI: Hematopoietic stem cell transplant comorbidity index; MSD: Matched sibling donor; MORD: Matched other related donor; MUD: Matched unrelated donor; CR: Complete remission; TBI: Total body irradiation; MAC: Myeloablative conditioning; RIC/NMA: Reduced intensity conditioning/non-myeloablative.

Table 2 Univariable and multivariable risk factors influencing post hematopoietic stem cell transplant outcome

		Univariable HR (95%CI; P value)	Multivariable HR (95%CI; P value)
PFS	Age at HCT	1.5 (0.27-6; P = 0.6)
	B-cell vs T-cell	0.53 (0.25-1.17; P = 0.11)
	ALL vs LBL	0.6 (0.27-1.45; P = 0.24)
	Female D → male R	0.87 (0.25-2.26; P = 0.79)
	Donorgender mismatch	0.53 (0.22-1.17; P = 0.12)
	MSD vs other	0.5 (0.22-1.28; P = 0.14)
	TBI regimen	1.1 (0.41-3.67; P = 0.89)
	MAC vs RIC/NMA	1.37 (0.41-8.5; P = 0.65)
	CR1 vs other	0.59 (0.28-1.28; P = 0.18)
	aGVHD	2.1 (0.95-4.5; P = 0.066)	3.14 (1.36-7.1; P = 0.008)
	cGVHD	0.43 (0.18-0.94; P = 0.033)	0.38 (0.15-0.89; P = 0.026)
OS	Age at HCT	1.02 (0.98-1.05; P = 0.28)
	B-cell vs T-cell	0.57 (0.24-1.37; P = 0.2)
	ALL vs LBL	0.44 (0.19-1.11; P = 0.08)
	Female D → male R	1.15 (0.33-3.1; P = 0.8)
	Donorgender mismatch	0.62 (0.23-1.48; P = 0.29)
	MSD vs other	1.27 (0.43-5.4; P = 0.69)
	TBI regimen	1.99 (0.58-12.5; P = 0.31)
	MAC vs RIC/NMA	0.69 (0.23-2.92; P = 0.56)
	CR1 vs other	0.5 (0.21-1.17; P = 0.11)
	aGVHD	3.35 (1.42-7.9; P = 0.006)	4.9 (1.99-12; P = 0.0007)
	cGVHD	0.4 (0.15-0.97; P = 0.043)	0.29 (0.1-0.67; P = 0.0044)

HCT: Hematopoietic stem cell transplant; ALL: Acute lymphoblastic leukemia; LBL: Lymphoblastic lymphoma; Ph: Philadelphia chromosome; MSD: Matched sibling donor; TBI: Total body irradiation; CR: Complete remission; MAC: Myeloablative conditioning; RIC/NMA: Reduced intensity conditioning/no myeloablative; a/cGVHD: Acute/chronic graft vs host disease.